COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT
COBRA PZF™ Coronary Stent System in Native Coronary Arteries for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term Dual Anti-Platelet Therapy. The PzF Shield Trial
Sponsor: CeloNova BioSciences, Inc.
A NA clinical study on Coronary Artery Disease, this trial is completed. The trial is conducted by CeloNova BioSciences, Inc. and has accumulated 9 data snapshots since 2013. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2022 — Jul 2024 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Jan 2021 — Jan 2022 [monthly]
Unknown Status NA
▶ Show 4 earlier versions
-
Mar 2020 — Jan 2021 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Mar 2020 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CeloNova BioSciences, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .